New London-based Advanced Therapy Treatment Centre
Paving the Way for Advanced Therapy Clinical Trials
We are excited to showcase the establishment of the London Advanced Therapies Treatment Centre (ATTC), a significant milestone in enhancing the infrastructure for advanced therapy clinical trials in the UK. This initiative is set to position London as a global leader in the field, driving an increase in commercial trial numbers and speed.
The new centre, a collaboration between Imperial College London, Kings College London, Queen Mary University of London, and University College London (UCL), along with their NHS Trusts, aims to leverage the expertise of these world-renowned institutions. The focus will be on improving the clinical trial infrastructure and facilitating greater patient access to potentially life-changing cell and gene therapies.
The London Advanced Therapies Treatment Centre joins the existing network of ATTC’s, including Innovate Manchester Advanced Therapy Centre Hub, Midlands-Wales ATTC, and Northern Alliance ATTC. This expansion is expected to enhance the overall capacity and capability of the UK’s advanced therapy clinical trial structure.
The ATTC network is coordinated by the CGT Catapult and receives funding from the National Institute for Health and Care Research (NIHR) and Innovate UK.
MedCity’s meeting with Kings College London (KCL) | 19th September
Our CEO Dr Angela Kukula and our Head of Life Sciences Nicki Bromwich, recently met with Professor Simon Howell from KCL to discuss the strategic importance of this development. The centre‘s role in accelerating the delivery of advanced therapy trials and its potential to attract more commercial trials to London was discussed. Mathew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, highlighted the importance of this new centre.
By fostering collaborations and leveraging London’s robust research ecosystem, we can significantly increase the number of advanced therapy trials conducted in the UK, ultimately benefiting patients and advancing medical science.
”With more advanced therapies in development and coming to clinical trials, there is a need to ensure that healthcare systems are supported to deliver these therapies on a larger scale. The new London Advanced Therapies ATTC, backed by world-leading academic and healthcare institutions, will increase the support the ATTC network provides across the UK and help more patients access the Advanced therapies they need.”
– Mathew Durdy, Chief Executive of the Cell and Gene Therapy Catapult